RxDoctor Payments Data

Veronica Ricks

Family · Hammond, LANPI 1174613947

Payments from drug & device makers

$710in general payments, 2019–2025

Across 20 payments — averaging $35.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sequel Med Tech, LLC$152
  • BETA Bionics, Inc.$139
  • Medtronic$130
  • Cequr Corporation$82
  • Dexcom, Inc.$53
  • Pfizer$39
  • plus $115 from 5 others

What the payments were for

  • Food & beverage$710100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$710 in reported general payments places this provider in the 55th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$14,171
Medicare patients
91
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol96$81,546
MounjaroTirzepatide54$73,514
TrulicityDulaglutide44$57,457
JardianceEmpagliflozin38$52,564
OzempicSemaglutide38$44,602
TradjentaLinagliptin41$35,379
JanuviaSitagliptin Phosphate38$34,452
EliquisApixaban40$34,450
RybelsusSemaglutide12$24,682
LinzessLinaclotide12$16,778
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$15,899
DapagliflozinDapagliflozin Propanediol15$8,185
Janumet XrSitagliptin Phos/Metformin Hcl12$7,998
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$7,742
Dexlansoprazole DrDexlansoprazole23$5,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$38$81,54696 claims
Novo NordiskOzempic, Rybelsus$16$69,28350 claims
PfizerEliquis$39$34,45040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,610 family providers in Louisiana.

Other family in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →